Latest News and Press Releases
Want to stay updated on the latest news?
-
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX® for the treatment of persistent, moderate to...
-
Finanskalender 2025 for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22. januar 2025: Stilleperiode19. februar 2025: Offentliggørelse af årsrapport 202413. marts 2025 kl. 16.00:...
-
2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report...
-
ALKs peanut-tablet påvist at være sikker og veltolereret på tværs af flere forskellige doserUdviklingen går nu ind i fase II, hvor dosisvalg og effekt undersøgesDe første patienter i fase II vil snart...
-
ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses...
-
ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at selskabets europæiske registreringsansøgning for ACARIZAX® (tabletvaccine mod husstøvmideallergi) hos børn i alderen fem til 11 år er blevet...
-
ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been...
-
The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet) phase 3 children...
-
Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet sales...
-
Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet...